Pharmaceutical Industry Reports Amebiasis Treatment Market | Page 2

REPORT DESCRIPTION
Amebiasis Treatment Market – Overview
Increasing approvals and launches of new drugs indicated for the treatment of amebiasis is expected to be a major
factor for growth of amebiasis treatment market. For instance, in 2017, Dr. Reddy's Laboratories received U.S.
Food and Drug Administration (FDA) approval for its Minolira (minocycline) extended-release tablets, indicated
for the treatment of a variety of bacterial infections and as adjunctive therapy in acute intestinal amebiasis.
Moreover, in 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Metronidazole
Tablets, 250mg and 500mg, generic version of Flagyl manufactured by G.D. Searle, LLC’s, indicated for the
treatment of amebiasis and a variety of anaerobic bacterial infections.
In 2016, Mylan Pharmaceuticals Inc. received ANDA approval for its Doryx (Doxycycline Hyclate) Delayed-
Release Tablets, 50 mg, indicated for the treatment of acute intestinal amebiasis. Furthermore, increasing
prevalence of amebiasis in region with poor sanitation facilities such as Africa and some countries in Asia Pacific
is expected to lead to increasing demand for its treatment, which in turn is expected to drive growth of the
amebiasis treatment market in the near future. For instance, according to data published by International Research
Journal of Biological Sciences, in 2013, the prevalence of amebiasis among school children in Lafia, Nigeria was
around 26.7%.